NextGen Sciences Launches Multiple Protein Plasma Biomarker Assay for Multiple Sclerosis

Share Article

NextGen Group plc (AIM:NGG) is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched the first phase of its multiple protein (multiplex) assays in plasma, for CNS diseases. The plasmamultiplesclerosis15 assay simultaneously measures 15 human plasma proteins that are thought to have potential as biomarkers in multiple sclerosis disease. The launch of plasmamultiplesclerosis15 is part of NextGen Sciences strategy of becoming a leading player in the growing central nervous system (CNS) and oncology biomarker markets.

NextGen Group plc (AIM:NGG) is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched the first phase of its multiple protein (multiplex) assays in plasma, for CNS diseases. The plasmamultiplesclerosis15 assay simultaneously measures 15 human plasma proteins that are thought to have potential as biomarkers in multiple sclerosis disease. The launch of plasmamultiplesclerosis15 is part of NextGen Sciences strategy of becoming a leading player in the growing central nervous system (CNS) and oncology biomarker markets.

NextGen’s assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. NextGen expects to continue to add candidate biomarker proteins to the plasmamultiplesclerosis15 assay, through its own R&D efforts and through collaborations and partnerships.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, ‘The release of plasmamultiplesclerosis15 demonstrates that we are very focused on the protein content of our assays to address the needs of our clients across different therapeutic areas. We continue to deliver on our plans to develop multiplex protein assays that will help to establish the company as a market leader in protein biomarker discovery and qualification.'

For more information please contact :

NextGen Group
Klaus Rosenau, Chairman and CEO
klaus(dot)rosenau(at)nextgensciences(dot)com
+49 160 551 6756

Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000

Notes to Editors

NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, http://www.marketsandmarkets.com) playing an important role. For more information please visit http://www.nextgensciences.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Klaus Rosenau, Chairman and CEO
NextGen Group
+49 160 551 6756
Email >

Jonathan Wright, Nicola Marrin
Seymour Pierce
+44 (0) 20 7107 8000
Visit website